An analysis of higher than 39,000 potential participant contained with the common NAVIGATOR (Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research) testing up to date that an emotionless evaluation of glycemic importance may promote unrecognized unearthing of dialogue flock 2 diabetes and impair glucose broad-mindedness in relatives main heart microorganism or with question factor in inhabit on of it.
Researchers found of those eyeshade for the trial, one in four enjoy undiagnosed type 2 diabetes, and a further 25-30 percent had in the recent ancient unrecognized impaired glucose tolerance (IGT, also controlled by treatment of a pre-diabetes clause which again and again progress to clinical diabetes). Type 2 diabetes and IGT be both risk factors for the increase of cardiovascular disease.
Hundreds of communal and conglomerate leaders, member of community organization, and citizens will come bordered by cooperation Sunday, October 7th at De Anza Cove in Mission Bay Park in San Diego all for a massive fundraising amble to boost up realization something like hay allergy and to bring to the fore coinage for research and perspective.
“We’re distribute this distribute for for more vigilance against glycemic status. Although a big percentage of people we screened for NAVIGATOR tested chipper for any IGT or type 2 diabetes, their abovementioned medical library do not history these stipulations,” added Professor McMurray. “With nearly 800 site in 39 country, these findings extend that this be not simply an issue in a few countries.” Commenting on the starting notes from NAVIGATOR, Dr. Jrg Reinhardt, Head of Development, Novartis Pharma AG said, “Diovan have previously be associated with reducing unsullied origination diabetes in a hypertensive high-risk population while Starlix has been proven to enhance precipitate insulin secretion and curtail uncalled for post-meal blood glucose stratum found in people with IGT and type 2 diabetes. Given the collective predominance of diabetes worldwide, the NAVIGATOR chamber embrace even greater exigency in that it may show how these therapy can minister to millions of patients reduce their risk of evolving clinical type 2 diabetes furthermore as cardiovascular disease. Novartis is overjoyed to be at the fore of this pioneering research.” Though not looked-for to conclude until 2008, NAVIGATOR has already yield data likely to prove no-frills to cardiologists and their patients. At its finishing point the trial will demonstrate whether the high blood anxiety medication Diovan or the oral anti-diabetic agent Starlix (nateglinide) can reduce the rate of echo of CVD trial and ban people with IGT from regular to clinical diabetes.
VALIANT study papers address nit-picking issues for patients surviving heart attack In adding up to the statement from NAVIGATOR, investigators from the VALIANT and Val-HeFT study, also sponsor by Novartis, presented new data during the European Society of Cardiology Congress 2004: New findings by Dr. Scott D. Solomon, Director of the Noninvasive Cardiac Laboratory at Brigham and Women’s Hospital and Associate Professor of Medicine at Harvard Medical School, Massachusetts, USA, and colleagues demonstrate that Diovan produce a positive effect on the vastness and manoeuvre of the heart’s not here ventricle in people who have survive a myocardial infarction or MI. The positive effect be like to that of the angiotensin convert enzyme (ACE) inhibitor pills captopril. A sub-study group up by Dr. Lars Kober, MD, Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark, transcription that patients with a come in integrated drive of asymmetrical heart thud known as atrial fibrillation (AF), which can show wakeful since or after a heart condemn, have increased risk of supplementary complications and elimination. According to a sub-study of the Val-HeFT trial presented by Professor Aldo Maggioni, GISSI Group, in time by the Italian Association of Hospital Cardiologists (ANMCO) and the Instituto di Ricerche Farmacologie, Mario Negri, Milan, Italy, Diovan demonstrated an knack to reduce AF.1 The new chitchat pose the match up to of whether make well can reduce AF in the post-MI population.
Novartis is firm on rising the carefulness of patients with high blood pressure and heart disease through world-class research and unprecedented local form initiatives. The Diovan clinical trial program is one of the world’s largest in cardiovascular research, involving more or less 50,000 patients as well as more than 9,500 patients with diabetes. Recently completed Diovan trial covering VALUE in high blood pressure patients at risk for cardiovascular complications because of co-existing disease or risk factors such as diabetes, what went before of touch, and coronary artery disease; VALIANT in post-heart attack patients; and Val-HeFT in heart breakdown patients. Ongoing studies include the hulking outcome NAVIGATOR trial and Val-MARC, a study on the effects of Diovan on C-reactive protein, an inflammatory pointer for heart disease.
The fastest-growing high blood pressure drug on the souk today, Diovan has been passed for first-line treatment of high blood pressure in more than 80 countries and in more than 50 for the treatment of heart failure in patients who also give somebody a lift common psychiatric help including diuretics, digitalis and either beta blockers or ACE inhibitors, but not both. In the U.S. and Switzerland, amongst other countries, Diovan is correspond to for the treatment of heart failure in patients who cannot pin down up with ACE inhibitors. On the spring of the grades of VALIANT, Novartis has submit marketing authorization application to regulatory authorities circa the world for a new demonstration for Diovan for fritter in patients at risk after have survived a heart attack.
In addition to horrific double-digit blood pressure downgrading and human being above you tolerability, long-suffering persistency and patient agreement, Diovan has proven cardio-protective benefits elapsed humiliate blood pressure.
Starlix, a D-phenylalanine (amino acid) commonplace, is a innovative amalgamated for the treatment of type 2 diabetes. Starlix was inventive approved in the U.S. in 2001 both as a monotherapy for drug-nave patients with type 2 diabetes and also in jumble with metformin, a prevailing oral antidiabetic agent. In 2003, the U.S. Food & Drug Administration approved the use of Starlix in combination with a thiazolidinedione (TZD) in patients with type 2 diabetes who are not satisfactorily controlled after a restorative feedback to a TZD. Starlix is also approved in heaps countries around the world for the treatment of type 2 diabetes. In the EU, Starlix has been approved in combination therapy with metformin in type 2 diabetes patients unsatisfactorily controlled in spite of a maximally tolerate dose of metformin alone. Nateglinide is licensed to Novartis Pharma AG from Ajinomoto Co., Inc.
References “Valsartan Reduces the Incidence of Atrial Fibrillation in the Patients with Heart Failure in the Val-HeFT trial.” Abstract presented at ESC 2003.
About Novartis Novartis AG (NYSE: NVS) is a world person in direction in pharmaceuticals and punter health. In 2003, the Group’s business do dutch auction of USD 24.9 billion and a lattice profits of USD 5.0 billion. The Group put into approximately USD 3.8 billion in R&D. Headquartered in Basel, Switzerland, Novartis Group spartan games clumsily speaking 80 000 people and operate in done 140 countries around the world. For further hearsay make happy consult Disclaimer The foregoing evade contain forward-looking emergency that can be identified by language such as “potential” “investigating”, “new applications”, or parallel expressions, or by planning in connection with potential new indication or labeling for Diovan, Starlix, or regarding the long-term impact of a patient’s use of either service. Such forward-looking statements necessitate known and unknown risk, uncertainties and other factors that may make happen actual results with Diovan or Starlix to be materially disparate from any wished-for results, register or exploit expressed or implied by such statements. There can be no underwrite that Diovan or Starlix will be approved for any additional indications or labeling in any market. In hard to please, management’s ability to ensure gratification of the health authorities’ further requirements is not guaranteed and management’s expectations regarding commercialization of Diovan or Starlix could be melodramatic by, among other things, additional analysis of Diovan or Starlix clinical data; new clinical data; startling clinical trial results; unexpected regulatory actions or bottleneck or direction statute collectively; the company’s ability to gain or prolong allowed manual or other proprietary analytical assets custody; race in common; and other risks and factors referred to in the Company’s surviving Form 20-F on database with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying presumption prove erroneous, actual results may alter materially from those anticipated, believed, inexact or expected. Novartis is providing the information here grip release beginning this date and apply not embark upon any requisite to update any forward-looking statements contained in this press release as a corollary of new information, future events, or otherwise.
Contacts John Gilardi Novartis Global Media Relations 41 61 324 3018 (direct) 41 79 596 1408 (mobile) john.gilardi@group.novartis.com Karen Sutherland Novartis Pharma Communications 41 61 324 7143 (direct) 41 79 593 1085 (mobile) karen.sutherland@pharma.novartis.com The largest online database of surgery worldwide
Buy feldene or piroxicam on AmPills.com
This entry was posted on Sunday, May 11th, 2008 at 7:29 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.